Stryker (SYK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
29 Jan

For the quarter ended December 2024, Stryker (SYK) reported revenue of $6.44 billion, up 10.7% over the same period last year. EPS came in at $4.01, compared to $3.46 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $6.35 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +3.62%, with the consensus EPS estimate being $3.87.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Sales by Geography- International: $1.56 billion versus $1.63 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
  • Net Sales by Geography- United States: $4.87 billion versus $4.68 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.9% change.
  • Net Sales by Business- Orthopaedics and Spine: $2.55 billion versus $2.59 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
  • Net Sales by Business- MedSurg and Neurotechnology: $3.88 billion compared to the $3.76 billion average estimate based on nine analysts. The reported number represents a change of +13.3% year over year.
  • Net Sales by Business- Orthopaedics and Spine- Knees: $687 million versus $673.11 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
  • Net Sales by Business- Orthopaedics and Spine- Spine: $186 million versus $337.22 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -41.5% change.
  • Net Sales by Business- Orthopaedics and Spine- Hips: $463 million versus $457.61 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +11.8% change.
  • Net Sales by Business- Orthopaedics and Spine- Other: $222 million compared to the $176.23 million average estimate based on seven analysts. The reported number represents a change of +33.7% year over year.
  • Net Sales by Business- Orthopaedics and Spine- Trauma and Extremities: $996 million versus the seven-analyst average estimate of $935.04 million. The reported number represents a year-over-year change of +15.8%.
  • Net Sales by Business- MedSurg and Neurotechnology- Instruments: $790 million compared to the $811.02 million average estimate based on seven analysts. The reported number represents a change of +7.3% year over year.
  • Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $1.01 billion versus $971 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.
  • Net Sales by Business- MedSurg and Neurotechnology- Medical: $1.14 billion versus the seven-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +9.6%.
View all Key Company Metrics for Stryker here>>>

Shares of Stryker have returned +10.4% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Stryker Corporation (SYK) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10